A Research Reboot of Tuberculosis on the Keystone Symposia 50th Anniversary

摘要 要求为题为"重新启动结核病研究“的Keystone专题讨论会提供支助， Keystone研讨会50周年，由Joseph Keane博士、Shabaana A.作者：Khader，托马斯，J. Scriba和Alan Sher。会议将于2022年1月23日至26日在科罗拉多州布雷肯里奇举行。 结核病（TB）是人类的一个古老的祸害，直到今天仍然是一个主要的死亡原因， 单一传染性病原体的全球死亡率仅被当前的COVID-19冠状病毒大流行超过。 然而，随着有效抗生素的出现和公共卫生措施的改善， 在世纪，结核病已大幅下降，许多人认为结核病注定会被根除。到1972年， 在基石研讨会成立的那一年，这一结论被不断增加的案件数量所推翻。 纽约市和其他城市地区后来受到艾滋病病毒合并感染的破坏性影响。这一重大 疾病的重新出现刺激了旨在征服结核病的密集研究的新时代。本次研讨会将 展示结核病研究人员在过去50年中取得的杰出突破，同时突出当前 该领域的进展。此外，还将特别关注最新的有希望的疫苗试验结果 发现和实施改进的抗生素治疗方案。该计划还将强调 我们对宿主-病原体相互作用的基本理解取得了令人兴奋的进展，特别是在 免疫代谢，导致新的宿主定向治疗靶点的鉴定。主旨 讲座将概述主要成就，同时探讨全球结核病的现状，以及 病毒流行对结核病研究和控制的影响。总的来说，该计划将推动 为实现我们根除结核病的最终目标而努力。

ABSTRACT Support is requested for a Keystone Symposia conference entitled A Research Reboot of Tuberculosis on the Keystone Symposia 50th Anniversary, organized by Drs. Joseph Keane, Shabaana A. Khader, Thomas J. Scriba and Alan Sher. The conference will be held in Breckenridge, Colorado from January 23-26, 2022. Tuberculosis (TB) is an ancient scourge of mankind that still to this day remains a leading cause of death by a single infectious agent only surpassed in its global mortality by the current COVID-19 coronavirus pandemic. Nevertheless, with the advent of effective antibiotics and improved public health measures, in the middle of the 20th century, TB had substantially declined and was thought by many to be destined for eradication. By 1972, the year of the founding of the Keystone Symposia, this conclusion was quashed by expanding caseloads in New York City and other urban areas and later by the devastating impact of HIV-coinfection. This major disease re-emergence stimulated a new era of intense research aimed at conquering TB. This symposium will showcase the outstanding breakthroughs of TB researchers over the last 50 years, while highlighting current advances in the field. Special attention will be given to the results of the latest promising vaccine trials, as well the discovery and implementation of improved antibiotic regimens. This program will also emphasize the exciting advances in our basic understanding of the host-pathogen interaction, and in particular in the area of immunometabolism, that are leading to the identification of new host-directed treatment targets. Keynote lectures will overview the major achievements, while exploring the current state of global tuberculosis, as well as the impact of viral pandemics on tuberculosis research and control. Taken together, the program will propel the field forward toward achievement of our ultimate goal of TB eradication.